No Data
Daily Bull and Bear | Hang Seng Index latest bull and bear street goods ratio is 54:46; wuxi bio surged nearly 8%, multiple call options soared over 100%
As of the close, the market turnover was 126.683 billion Hong Kong dollars; the total turnover of all bull and bear warrants was 13.08 billion Hong Kong dollars, accounting for 10.3% of the market turnover, with good position accounting for 6.5% and light position accounting for 3.8%.
The concept of contract research organizations is popular. Wuxi Bio (02269) rose by 7.48%. Institutions point out that CRO/CDMO may gradually emerge from a clear turning point next year.
Jingu Finance News | The concept of contract research organizations has generally risen, with Wuxi Bio (02269) up 7.48%, Wuxi Apptec (02359) up 6.12%, Pharmaron (03759) up 2.8%, Genscript Bio (01548) up 1.87%, Asymchem Laboratories (06821) up 1.44%. Zhongtai's research report pointed out that in early November, the pharmaceutical industry, which was at a low point, ushered in a strong rebound, followed by a volatile adjustment along with the large cap. Internally within the sector, driven by policies such as the prepaid medical insurance funds and the release of the medical insurance list, both the pharmaceutical commerce and innovative drugs subsectors have performed well. The healthcare policies
Hong Kong stock market midday review | The three major indexes rebounded after testing the lows, with the Hang Seng Index rising by 0.36%; biomedical stocks were strong, with Global New Materials up over 11% and wuxi apptec up over 5%.
Network technology stocks showed mixed performance, with Bilibili-W up 2.39% and Meituan-W down 2.33%; semiconductor stocks generally fell, with Ingdan dropping 3.70% and Solomon Systech down 2.04%; electrical utilities stocks strengthened, with CGN Power up 3.09% and CKI Holdings up 3.08%.
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
The National Medical Insurance Administration: Negotiated pharmaceuticals during the agreement period have reduced the financial burden on patients by over 880 billion yuan.
This morning, the National Medical Insurance Administration announced the new version of the pharmaceutical catalog at a press conference. A responsible official from the National Medical Insurance Administration stated at the meeting that since its establishment, the speed of new drugs entering the catalog has continuously accelerated, allowing insured individuals to enjoy the benefits brought by pharmaceutical innovation in a timely manner. As of the end of October this year, the cumulative number of beneficiaries from negotiated pharmaceutical products during the agreement period reached 0.83 billion people, alleviating the financial burden on patients by more than 880 billion yuan. With more new drugs entering the catalog, the level of benefits for patients will steadily improve, which will effectively enhance the confidence of the pharmaceutical industry in increasing research and development innovation, conducive to better promoting economic and social development.
The new national medical insurance pharmaceutical list adds 91 types of pharmaceuticals, expecting to reduce the burden on patients by over 50 billion RMB next year.
The National Medical Insurance Bureau announced the new version of the pharmaceutical catalog at a press conference this morning. The criteria for the adjustment of this year's medical insurance catalog mainly include pharmaceuticals that have been newly launched or have modified descriptions in the past five years, medicines for rare diseases, children's drugs and generic drugs encouraged by the state for research and development, as well as essential drugs. Following the appropriate procedures, a total of 91 new pharmaceutical products have been added, including: 26 tumor drugs, 15 drugs for chronic diseases such as diabetes, 13 drugs for rare diseases, 7 anti-infection drugs, 11 chinese patent medicines, 4 psychiatric drugs, and 21 drugs from other fields. In this year's negotiation/bidding session, a total of 117 off-catalog pharmaceutical products participated.
No Data
No Data